Satou H, Kamano T, Izumi T, Yoshida M
Gan To Kagaku Ryoho. 1986 Sep;13(9):2807-12.
Sunrabim for injection (BH-AC), one of the antitumor agents available for acute leukemia, has considerable activity against a variety of transplanted solid tumors in rats and mice. A comparative clinical study was performed by randomized controlled trial on two different combined chemotherapies of MMC, 5-FU (MF group), and MMC, 5-FU, BH-AC (MF . BH-AC group) for 64 patients with a variety of solid cancers. Among 64 patients, 47 were evaluable for response (MF group: 23/32, MF . BH-AC group: 24/32). The partial response rate of the MF group was 4.3% (1/23), and that of the MF . BH-AC group was 33.3% (8/24). MF . BH-AC therapy was found to be more effective than MF therapy. The toxicity rates of the two therapies were similar (MF group: 46.7%, MF . BH-AC group: 50.0%). This study suggests that combined chemotherapy of MF plus BH-AC is more effective on a variety of solid cancers in comparison to MF therapy.
注射用顺氯氨铂（BH-AC）是一种可用于治疗急性白血病的抗肿瘤药物，对大鼠和小鼠的多种移植性实体瘤具有显著活性。我们通过随机对照试验对64例患有各种实体癌的患者进行了一项比较临床研究，比较了丝裂霉素（MMC）、5-氟尿嘧啶（5-FU）联合化疗（MF组）和MMC、5-FU、BH-AC联合化疗（MF.BH-AC组）的疗效。64例患者中，47例可评估疗效（MF组：23/32，MF.BH-AC组：24/32）。MF组的部分缓解率为4.3%（1/23），MF.BH-AC组为33.3%（8/24）。结果发现，MF.BH-AC疗法比MF疗法更有效。两种疗法的毒性发生率相似（MF组：46.7%，MF.BH-AC组：50.0%）。本研究表明，与MF疗法相比，MF联合BH-AC的联合化疗对各种实体癌更有效。
